Omnicell Inc

OMCL

Equity

ISIN US68213N1090 / Valor 1275961

NASDAQ (2025-04-04)

USD 32.69-3.97%

Omnicell Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Omnicell Inc is a company specializing in medication management solutions and supporting infrastructure. Their core business focuses on providing innovative technology to help healthcare facilities streamline medication dispensing processes and improve patient safety. Omnicell Inc has been recognized for their commitment to data protection and cybersecurity, ensuring the secure management of sensitive information within the healthcare industry. With a strong reputation for quality and reliability, Omnicell Inc continues to be a leader in the healthcare technology sector, offering cutting-edge solutions to meet the evolving needs of healthcare providers.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Overview

Omnicell Inc. reported total revenues of $282 million for the third quarter of 2024. This represents a decrease of $16 million, or 5%, compared to the third quarter of 2023. The decline in revenue is attributed to a challenging environment for some health system customers and the timing of the XT Series automated dispensing systems lifecycle.

Net Income

For the third quarter of 2024, Omnicell Inc. achieved a GAAP net income of $9 million, translating to $0.19 per diluted share. This is an improvement from the GAAP net income of $6 million, or $0.12 per diluted share, reported in the same quarter of the previous year.

Non-GAAP Earnings

Omnicell Inc.'s non-GAAP net income for the third quarter of 2024 was $26 million, or $0.56 per diluted share. This is slightly lower than the non-GAAP net income of $28 million, or $0.62 per diluted share, recorded in the third quarter of 2023.

Balance Sheet Highlights

As of September 30, 2024, Omnicell Inc. had cash and cash equivalents totaling $571 million and total debt of $572 million. The company's total assets amounted to $2.3 billion, with cash flows from operating activities reaching $23 million for the quarter.

2024 Financial Guidance

Omnicell Inc. has updated its 2024 financial guidance, expecting full-year total revenues to range between $1.100 billion and $1.110 billion. The company anticipates non-GAAP earnings per share to be between $1.65 and $1.72, with non-GAAP EBITDA projected to be between $129 million and $134 million for the year.

Summarized from source with an LLMView Source

Key figures

18.5%1Y

-74.3%3Y

-49.9%5Y

Performance

56.3%1Y

55.6%3Y

49.9%5Y

Volatility